Athersys, Inc. announced that its partner, HEALIOS K.K. provided updates on its two clinical programs evaluating MultiStem® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.
[Athersys, Inc.]
6445212
BBBBBBBB
items
1
apa
0
default
asc
1
173607
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
